Zim Laboratories Limited Cash Flow Conversion Efficiency

Latest as of September 2023: 0.036x

Zim Laboratories Limited cash flow conversion efficiency. Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) has a cash flow conversion efficiency ratio of 0.036x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs81.71 Million ≈ $883.66K USD) by net assets (Rs2.26 Billion ≈ $24.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Zim Laboratories Limited (2013–2025)

Cash flow conversion efficiency of Zim Laboratories Limited from 2013 to 2025. This chart illustrates how Zim Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Zim Laboratories Limited for real-time trading data and today's change.

Zim Laboratories Limited Cash Flow Conversion Ratio Explained

Zim Laboratories Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Zim Laboratories Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zim Laboratories Limited ranked by their cash flow conversion efficiency. Also see Zim Laboratories Limited market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Geodrill Ltd
F:7GD
-0.022x
Alithya Group Inc
NASDAQ:ALYAF
-0.048x
Kervansaray Yatirim Holding AS
IS:KERVN
0.067x
SMJ International Holdings Inc.
NYSE MKT:SMJF
N/A
Powerlong Real Estate Holdings Limited
F:PW5
0.017x
Sandon Capital Investments Ltd
AU:SNC
0.061x
Novita S.A.
WAR:NVT
0.082x
Martin Midstream Partners LP
NASDAQ:MMLP
0.015x

Annual Cash Flow Conversion Efficiency for Zim Laboratories Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Zim Laboratories Limited from 2013 to 2025. Review how much free cash does Zim Laboratories Limited generate to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs2.52 Billion
≈ $27.28 Million
Rs411.55 Million
≈ $4.45 Million
0.163x +139.30%
2024-03-31 Rs2.39 Billion
≈ $25.82 Million
Rs162.78 Million
≈ $1.76 Million
0.068x -63.59%
2023-03-31 Rs2.00 Billion
≈ $21.67 Million
Rs375.19 Million
≈ $4.06 Million
0.187x -33.13%
2022-03-31 Rs1.76 Billion
≈ $19.00 Million
Rs492.06 Million
≈ $5.32 Million
0.280x +41.33%
2021-03-31 Rs1.61 Billion
≈ $17.38 Million
Rs318.51 Million
≈ $3.44 Million
0.198x +39.07%
2020-03-31 Rs1.54 Billion
≈ $16.64 Million
Rs219.15 Million
≈ $2.37 Million
0.142x -38.25%
2019-03-31 Rs1.51 Billion
≈ $16.34 Million
Rs348.65 Million
≈ $3.77 Million
0.231x -13.92%
2018-03-31 Rs1.37 Billion
≈ $14.77 Million
Rs366.13 Million
≈ $3.96 Million
0.268x -1.11%
2017-03-31 Rs1.18 Billion
≈ $12.80 Million
Rs320.71 Million
≈ $3.47 Million
0.271x +21.46%
2016-03-31 Rs983.37 Million
≈ $10.63 Million
Rs219.43 Million
≈ $2.37 Million
0.223x +276.37%
2015-03-31 Rs942.10 Million
≈ $10.19 Million
Rs55.85 Million
≈ $604.04K
0.059x +105.44%
2014-03-31 Rs1.16 Billion
≈ $12.55 Million
Rs33.48 Million
≈ $362.11K
0.029x +113.30%
2013-03-31 Rs1.07 Billion
≈ $11.55 Million
Rs-231.81 Million
≈ $-2.51 Million
-0.217x --

About Zim Laboratories Limited

NSE:ZIMLAB India Drug Manufacturers - Specialty & Generic
Market Cap
$75.05 Million
Rs6.94 Billion INR
Market Cap Rank
#20120 Global
#1106 in India
Share Price
Rs142.39
Change (1 day)
+5.65%
52-Week Range
Rs60.26 - Rs152.63
All Time High
Rs152.63
About

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more